Literature DB >> 24136184

The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL.

C F Ng1, Peter K F Chiu, N Y Lam, H C Lam, Kim W M Lee, Simon S M Hou.   

Abstract

PURPOSE: To investigate the role of the Prostate Health Index (phi) in prostate cancer (PCa) detection in patients with a prostate-specific antigen (PSA) level of 4-10 ng/mL receiving their first prostatic biopsy in an Asian population.
METHODS: This was a retrospective study of archived serum samples from patients enlisted in our tissue bank. Patients over 50 years old, with PSA level of 4-10 ng/mL, a negative digital rectal examination, and received their first prostatic biopsy between April 2008 and April 2013, were recruited. The serum sample collected before biopsy was retrieved for the measurement of various PSA derivatives and the phi value was calculated for each patient. The performance of these parameters in predicting the prostatic biopsy results was assessed.
RESULTS: Two hundred and thirty consecutive patients, with 21 (9.13 %) diagnosed with PCa, were recruited for this study. Statistically significant differences between PCa patients and non-PCa patients were found for total PSA, PSA density, [-2]proPSA (p2PSA), free-to-total PSA ratio (%fPSA), p2PSA-to-free PSA ratio (%p2PSA), and phi. The areas under the curve of the receiver operating characteristic curve for total PSA, PSA density, %fPSA, %p2PSA, and phi were 0.547, 0.634, 0.654, 0.768, and 0.781, respectively. The phi was the best predictor of the prostatic biopsies results. At a sensitivity of 90 %, the use of the phi could have avoided unnecessary biopsies in 104 (45.2 %) patients.
CONCLUSIONS: Use of the phi could improve the accuracy of PCa detection in patients with an elevated PSA level and thus avoid unnecessary prostatic biopsies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24136184     DOI: 10.1007/s11255-013-0582-0

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  19 in total

1.  Cost-effectiveness of Prostate Health Index for prostate cancer detection.

Authors:  Michael B Nichol; Joanne Wu; Joice Huang; Dwight Denham; Stanley K Frencher; Steven J Jacobsen
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

2.  Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors.

Authors:  Osama M Zaytoun; Thomas Anil; Ayman S Moussa; Li Jianbo; Khaled Fareed; J Stephen Jones
Journal:  Urology       Date:  2011-02-12       Impact factor: 2.649

Review 3.  Prostate-specific antigen screening: pro.

Authors:  Stacy Loeb; William J Catalona
Journal:  Curr Opin Urol       Date:  2010-05       Impact factor: 2.309

4.  Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).

Authors:  Monique J Roobol; Fritz H Schröder; Geert L J H van Leenders; Daphne Hessels; Roderick C N van den Bergh; Tineke Wolters; Pim J van Leeuwen
Journal:  Eur Urol       Date:  2010-09-26       Impact factor: 20.096

5.  Pre-treatment risk stratification of prostate cancer patients: A critical review.

Authors:  George Rodrigues; Padraig Warde; Tom Pickles; Juanita Crook; Michael Brundage; Luis Souhami; Himu Lukka
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

6.  Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access prostate-specific antigen assays.

Authors:  Catherine Fillée; Bertrand Tombal; Marianne Philippe
Journal:  Clin Chem Lab Med       Date:  2010-02       Impact factor: 3.694

7.  Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range.

Authors:  Kazuto Ito; Mai Miyakubo; Yoshitaka Sekine; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuhiro Suzuki
Journal:  World J Urol       Date:  2012-08-18       Impact factor: 4.226

8.  Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.

Authors:  Carsten Stephan; Sébastien Vincendeau; Alain Houlgatte; Henning Cammann; Klaus Jung; Axel Semjonow
Journal:  Clin Chem       Date:  2012-12-04       Impact factor: 8.327

9.  A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy.

Authors:  Lori J Sokoll; William Ellis; Paul Lange; Jennifer Noteboom; Debra J Elliott; Ina L Deras; Amy Blase; Seongjoon Koo; Mark Sarno; Harry Rittenhouse; Jack Groskopf; Robert L Vessella
Journal:  Clin Chim Acta       Date:  2007-11-17       Impact factor: 3.786

Review 10.  PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.

Authors:  Jeffrey Tosoian; Stacy Loeb
Journal:  ScientificWorldJournal       Date:  2010-10-01
View more
  24 in total

Review 1.  Serum markers in prostate cancer detection.

Authors:  Ola Bratt; Hans Lilja
Journal:  Curr Opin Urol       Date:  2015-01       Impact factor: 2.309

2.  Assessment of men's risk thresholds to proceed with prostate biopsy for the early detection of prostate cancer.

Authors:  Kevin Koo; Elias S Hyams
Journal:  Int Urol Nephrol       Date:  2019-06-11       Impact factor: 2.370

Review 3.  Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen.

Authors:  Kazuto Ito; Yuji Fujizuka; Kiyohide Ishikura; Bernard Cook
Journal:  Int J Clin Oncol       Date:  2014-08-20       Impact factor: 3.402

4.  The prostate health index selectively identifies clinically significant prostate cancer.

Authors:  Stacy Loeb; Martin G Sanda; Dennis L Broyles; Sanghyuk S Shin; Chris H Bangma; John T Wei; Alan W Partin; George G Klee; Kevin M Slawin; Leonard S Marks; Ron H N van Schaik; Daniel W Chan; Lori J Sokoll; Amabelle B Cruz; Isaac A Mizrahi; William J Catalona
Journal:  J Urol       Date:  2014-11-15       Impact factor: 7.450

Review 5.  Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer.

Authors:  Ya-Qiang Huang; Tong Sun; Wei-De Zhong; Chin-Lee Wu
Journal:  Am J Clin Exp Urol       Date:  2014-12-25

6.  Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use.

Authors:  Tingting He; Mengzhe Wang; Hui Wang; Hongpei Tan; Yongxiang Tang; Eric Smith; Zhanhong Wu; Weihua Liao; Shuo Hu; Zibo Li
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-01       Impact factor: 9.236

7.  Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume.

Authors:  Peter K F Chiu; Monique J Roobol; Jeremy Y Teoh; Wai-Man Lee; Siu-Ying Yip; See-Ming Hou; Chris H Bangma; Chi-Fai Ng
Journal:  Int Urol Nephrol       Date:  2016-06-27       Impact factor: 2.370

Review 8.  Clinical Utility of Biomarkers in Localized Prostate Cancer.

Authors:  Michael S Leapman; Hao G Nguyen; Matthew R Cooperberg
Journal:  Curr Oncol Rep       Date:  2016-05       Impact factor: 5.075

9.  Development and external validation of a prostate health index-based nomogram for predicting prostate cancer.

Authors:  Yao Zhu; Cheng-Tao Han; Gui-Ming Zhang; Fang Liu; Qiang Ding; Jian-Feng Xu; Adriana C Vidal; Stephen J Freedland; Chi-Fai Ng; Ding-Wei Ye
Journal:  Sci Rep       Date:  2015-10-16       Impact factor: 4.379

Review 10.  Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer.

Authors:  Jeong Hyun Kim; Sung Kyu Hong
Journal:  Biomed Res Int       Date:  2015-08-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.